MEP35908A - Treatment of hypertension in women receiving hormone replacement therapy - Google Patents
Treatment of hypertension in women receiving hormone replacement therapyInfo
- Publication number
- MEP35908A MEP35908A MEP-359/08A MEP35908A MEP35908A ME P35908 A MEP35908 A ME P35908A ME P35908 A MEP35908 A ME P35908A ME P35908 A MEP35908 A ME P35908A
- Authority
- ME
- Montenegro
- Prior art keywords
- replacement therapy
- hormone replacement
- hypertension
- treatment
- women receiving
- Prior art date
Links
- 238000002657 hormone replacement therapy Methods 0.000 title abstract 3
- 206010020772 Hypertension Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000036772 blood pressure Effects 0.000 abstract 1
- 229940077130 drospirenone and estrogen Drugs 0.000 abstract 1
- 239000005555 hypertensive agent Substances 0.000 abstract 1
- 230000001631 hypertensive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/553—Renin inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37543902P | 2002-04-26 | 2002-04-26 | |
| PCT/US2003/012596 WO2003090755A1 (en) | 2002-04-26 | 2003-03-24 | Treatment of hypertension in women receiving hormone replacement therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP35908A true MEP35908A (en) | 2011-02-10 |
Family
ID=29270642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-359/08A MEP35908A (en) | 2002-04-26 | 2003-03-24 | Treatment of hypertension in women receiving hormone replacement therapy |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20040034001A1 (sr) |
| EP (2) | EP1499323A1 (sr) |
| JP (1) | JP2005528408A (sr) |
| KR (1) | KR20040104632A (sr) |
| CN (1) | CN1649596A (sr) |
| AU (2) | AU2003239162A1 (sr) |
| BR (1) | BR0309780A (sr) |
| CA (1) | CA2483554A1 (sr) |
| CR (1) | CR7571A (sr) |
| EC (1) | ECSP045456A (sr) |
| HK (1) | HK1079997A1 (sr) |
| HR (1) | HRP20041121A2 (sr) |
| IL (1) | IL164808A0 (sr) |
| ME (1) | MEP35908A (sr) |
| MX (1) | MXPA04010682A (sr) |
| NO (1) | NO20045147L (sr) |
| NZ (1) | NZ548754A (sr) |
| PL (1) | PL372055A1 (sr) |
| RS (1) | RS93804A (sr) |
| RU (1) | RU2373940C2 (sr) |
| UA (1) | UA87437C2 (sr) |
| WO (1) | WO2003090755A1 (sr) |
| ZA (1) | ZA200409548B (sr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| US7786101B2 (en) * | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
| DE102004016779A1 (de) * | 2004-04-01 | 2006-01-19 | Schering Ag | Drospirenonhaltige Zubereitungen zur transdermalen Anwendung |
| WO2005118166A2 (en) | 2004-06-04 | 2005-12-15 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical composition containing irbesartan |
| US20070275941A1 (en) * | 2006-05-17 | 2007-11-29 | Vladimir Hanes | Salt sensitivity and prevention of hypertension with drospirenone |
| US20090035373A1 (en) * | 2007-07-31 | 2009-02-05 | Katrin Mittmann | Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same |
| US20090035374A1 (en) * | 2007-07-31 | 2009-02-05 | Katrin Mittmann | Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same |
| KR20130097073A (ko) * | 2010-04-15 | 2013-09-02 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 초저-용량의 ｈｒｔ용 고체 경구 투여 형태 |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| RU2648470C2 (ru) * | 2016-03-03 | 2018-03-26 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) | Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217347A (en) * | 1977-12-27 | 1980-08-12 | E. R. Squibb & Sons, Inc. | Method of treating hypertension and medicaments therefor |
| US5001113A (en) | 1987-10-14 | 1991-03-19 | Merck & Co., Inc. | Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA |
| US6300361B1 (en) | 1990-07-25 | 2001-10-09 | Novartis Ag | Stabilized pharmaceutical compositions comprising acid donors |
| DE4344462C2 (de) * | 1993-12-22 | 1996-02-01 | Schering Ag | Zusammensetzung für die Empfängnisverhütung |
| US5922349A (en) * | 1995-09-28 | 1999-07-13 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| US6083528A (en) | 1995-09-28 | 2000-07-04 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| KR0156678B1 (ko) | 1996-01-11 | 1998-10-15 | 이상윤 | 안지오텐신 전환효소 저해제 |
| US5789442A (en) * | 1996-01-18 | 1998-08-04 | Schering Aktiengesellschaft | Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents |
| DE19633685C1 (de) | 1996-08-12 | 1997-10-09 | Schering Ag | Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens |
| DE19651000A1 (de) * | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
| UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| DK1380301T3 (da) * | 1999-08-31 | 2009-04-20 | Bayer Schering Pharma Ag | Farmaceutisk sammensætning af ethinylestradiol og drospirenon til anvendelse som svangerskabsforebyggende middel |
| US20030096798A1 (en) * | 1999-11-09 | 2003-05-22 | Williams Gordon H. | Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist |
| AU2001225413B2 (en) * | 2000-01-18 | 2005-06-23 | Bayer Schering Pharma Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| DK1313485T3 (da) * | 2000-08-28 | 2005-12-27 | Pharmacia Corp | Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion |
| US7786101B2 (en) * | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
-
2003
- 2003-03-24 BR BR0309780-3A patent/BR0309780A/pt not_active IP Right Cessation
- 2003-03-24 RU RU2004134571/14A patent/RU2373940C2/ru not_active IP Right Cessation
- 2003-03-24 EP EP03733879A patent/EP1499323A1/en not_active Ceased
- 2003-03-24 NZ NZ548754A patent/NZ548754A/en not_active IP Right Cessation
- 2003-03-24 MX MXPA04010682A patent/MXPA04010682A/es unknown
- 2003-03-24 RS YU93804A patent/RS93804A/sr unknown
- 2003-03-24 HR HR20041121A patent/HRP20041121A2/hr not_active Application Discontinuation
- 2003-03-24 EP EP08075587A patent/EP1982719A1/en not_active Withdrawn
- 2003-03-24 PL PL03372055A patent/PL372055A1/xx not_active Application Discontinuation
- 2003-03-24 CA CA002483554A patent/CA2483554A1/en not_active Abandoned
- 2003-03-24 JP JP2003587389A patent/JP2005528408A/ja active Pending
- 2003-03-24 KR KR10-2004-7017196A patent/KR20040104632A/ko not_active Ceased
- 2003-03-24 AU AU2003239162A patent/AU2003239162A1/en not_active Abandoned
- 2003-03-24 UA UA20041109649A patent/UA87437C2/ru unknown
- 2003-03-24 CN CNA038093871A patent/CN1649596A/zh active Pending
- 2003-03-24 HK HK06100150.0A patent/HK1079997A1/zh unknown
- 2003-03-24 WO PCT/US2003/012596 patent/WO2003090755A1/en not_active Ceased
- 2003-03-24 IL IL16480803A patent/IL164808A0/xx unknown
- 2003-03-24 ME MEP-359/08A patent/MEP35908A/xx unknown
- 2003-04-24 US US10/421,940 patent/US20040034001A1/en not_active Abandoned
-
2004
- 2004-11-05 CR CR7571A patent/CR7571A/es not_active Application Discontinuation
- 2004-11-25 ZA ZA200409548A patent/ZA200409548B/xx unknown
- 2004-11-25 NO NO20045147A patent/NO20045147L/no not_active Application Discontinuation
- 2004-11-26 EC EC2004005456A patent/ECSP045456A/es unknown
-
2008
- 2008-08-04 AU AU2008203497A patent/AU2008203497A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04010682A (es) | 2004-12-13 |
| KR20040104632A (ko) | 2004-12-10 |
| WO2003090755A1 (en) | 2003-11-06 |
| HK1079997A1 (zh) | 2006-04-21 |
| NO20045147L (no) | 2005-01-18 |
| CR7571A (es) | 2006-02-07 |
| AU2008203497A1 (en) | 2008-08-28 |
| IL164808A0 (en) | 2005-12-18 |
| BR0309780A (pt) | 2005-03-22 |
| UA87437C2 (ru) | 2009-07-27 |
| NZ548754A (en) | 2008-06-30 |
| EP1499323A1 (en) | 2005-01-26 |
| HRP20041121A2 (en) | 2005-02-28 |
| US20040034001A1 (en) | 2004-02-19 |
| ZA200409548B (en) | 2010-05-26 |
| AU2003239162A1 (en) | 2003-11-10 |
| ECSP045456A (es) | 2005-01-28 |
| RU2373940C2 (ru) | 2009-11-27 |
| CN1649596A (zh) | 2005-08-03 |
| RU2004134571A (ru) | 2005-07-10 |
| EP1982719A1 (en) | 2008-10-22 |
| CA2483554A1 (en) | 2003-11-06 |
| RS93804A (sr) | 2006-10-27 |
| JP2005528408A (ja) | 2005-09-22 |
| PL372055A1 (en) | 2005-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA87437C2 (ru) | Лечение гипертензии у женщин, которые поддаются гормонзаместительной терапии | |
| PA8612401A1 (es) | Solvato acetonico del dimetoxi docetaxel y su procedimiento de preparacion | |
| ATE412387T1 (de) | Medizinische vorrichtungen | |
| DK1459749T3 (da) | (S,S)-reboxetin til behandling af inkontinens | |
| CR8012A (es) | Clavo endomedular destinado al tratamiento de fracturas de femur proximal | |
| AU5338401A (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| DE60118544D1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
| AU2003260491A1 (en) | Vascular prosthesis, especially for replacing the ascending aorta | |
| CR7610A (es) | Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona | |
| CY1108453T1 (el) | Διαδικασια για την παρασκευη επλερενονης | |
| AU2003272300A8 (en) | Medical devices comprising a molybdenunm/rhenium alloy | |
| ES2216630T3 (es) | Metodos de tratar la hipertension dependiente de la sal. | |
| WO2001062784A3 (en) | Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer | |
| AU5628800A (en) | Substituted benzamide inhibitors of rhinovirus 3c protease | |
| MY135441A (en) | Therapeutic treatment | |
| AR043013A1 (es) | Composicion farmaceutica destinada al tratamiento de la endometriosis | |
| PE20050665A1 (es) | ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL | |
| DK1441714T3 (da) | Kombinationer omfattende en selektiv cyclooxygenase-2-inhibitor | |
| DK1635843T3 (da) | Terapi, der omfatter dienogest for hormonerstatning og depression | |
| ATE324887T1 (de) | Citalopram zur behandlung von bluthochdruck | |
| AR039477A1 (es) | Terapia de reemplazo hormonal | |
| TW200505407A (en) | A novel method for treatment and control of hypertension | |
| Bhandari | Bina Deewaron Ke Ghar | |
| UA49495A (uk) | Спосіб лікування переломів кісток | |
| UA32263A (uk) | Спосіб діагностики некрозу при гострій кишковій непрохідності |